Ashley Bonnell
Family · Knoxville, TNNPI 1013521285
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,307 of the $49,226 with a category attached, or 65.6%. EMD Serono, Inc. accounts for 69.6% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2024 at $19,772 and has fallen 53.7% since, to $9,158 in 2025. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 580 payments — averaging $84.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$34K
- E.r. Squibb & Sons, L.L.C.$4K
- Biogen$2K
- Novartis$1K
- Bristol Myers Squibb$1K
- AstraZeneca$948
- plus $5K from 37 others
What the payments were for
- Consulting fees$6501%
- Speaking & faculty fees$32,30766%
- Travel & lodging$9782%
- Food & beverage$14,89930%
- Education$3921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,226 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 96 | $934,151 |
| ZeposiaOzanimod Hydrochloride | 16 | $202,664 |
| TysabriNatalizumab | 17 | $141,590 |
| Avonex (4 Pack)Interferon Beta-1a | 14 | $134,426 |
| AubagioTeriflunomide | 13 | $120,967 |
| Teriflunomide | 29 | $56,847 |
| Dalfampridine ErDalfampridine | 64 | $47,643 |
| GlatopaGlatiramer Acetate | 13 | $31,980 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 39 | $1,323 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 20 | $1,001 |
| Baclofen | 59 | $729 |
| AmantadineAmantadine Hcl | 13 | $693 |
| Pregabalin | 24 | $457 |
| Gabapentin | 37 | $413 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTysabri, Avonex (4 Pack) | $2,094 | $276,01631 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $4,100 | $202,66416 claims |
| SanofiAubagio | $773 | $120,96713 claims |
| SandozGlatopa | $59 | $31,98013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Knoxville
- Dana WebberKnoxville$499K
- Tiffany SipeKnoxville$87K
- Stacey MaltmanKnoxville$34K
- Katherine JohnsonKnoxville$32K
- Ashley BellKnoxville$22K
- Carol HawkinsKnoxville$22K
- Mina FarrarKnoxville$21K
- Amy AllenKnoxville$21K
- Sarah HarderKnoxville$19K
- Stacy BrownMt Juliet$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.